Eli Lilly (LLY) PT Lifted to $102 at Piper Jaffray With Alimta EU Patent Concerns Lifted
Tweet Send to a Friend
Piper Jaffray analyst Richard Purkiss reiterated an Overweight rating and boosted his price target on Eli Lilly (NYSE: LLY) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE